Literature DB >> 15026348

Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.

Lin Qi1, Terry M Nett, Matthew C Allen, Xiaoming Sha, Gail S Harrison, Barbara A Frederick, E David Crawford, L Michael Glode.   

Abstract

Pokeweed antiviral protein (PAP) is a plant-derived, highly potent ribosome inactivating protein that causes inhibition of protein translation and rapid cell death. We and others have delivered this protein to various cell types, including cancer cells, using hormones to specifically target cells bearing the hormone receptor. Here, we compare binding and cytotoxicity of GnRH-PAP hormonotoxins prepared either by protein conjugation (GnRH-PAP conjugate) or through recombinant DNA technology (GnRH-PAP fusion). Although GnRH-PAP conjugate protein bound specifically to and caused cell death in cells bearing the gonadotropin-releasing hormone (GnRH) receptor, we could not detect binding or cytotoxicity using two different versions of the fusion protein in receptor-positive cells. We conclude that generation of an active GnRH-PAP fusion protein may not be feasible either because both ends of the GnRH molecule are required for receptor binding, but only the NH(2) terminus is free in the fusion protein and/or that more potent analogues of GnRH (inclusion of which is not feasible in the fusion protein) are needed for efficient targeting. In contrast, the GnRH-PAP conjugate shows promise as a novel anticancer agent, capable of targeting cancer cells expressing the GnRH receptor such as prostate, breast, ovarian, endometrial, and pancreatic cells. It may also be useful as a therapeutic agent to eliminate pituitary gonadotrophs, eliminating the need for chronic GnRH analogue administration to treat hormone-sensitive diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026348     DOI: 10.1158/0008-5472.can-3192-2

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Soapwort Saporin L3 Expression in Yeast, Mutagenesis, and RNA Substrate Specificity.

Authors:  Hongling Yuan; Quan Du; Matthew B Sturm; Vern L Schramm
Journal:  Biochemistry       Date:  2015-07-14       Impact factor: 3.162

2.  Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.

Authors:  Yong-Wen He; Chun-Xia Guo; Yan-Feng Pan; Cheng Peng; Zhi-Hong Weng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

3.  Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells.

Authors:  Amir Maleksabet; Hossein Zarei Jaliani; Amir Asgari; Amin Ramezani; Nasrollah Erfani
Journal:  Iran J Med Sci       Date:  2021-07

4.  Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.

Authors:  Azade Taheri; Rassoul Dinarvand; Fatemeh Atyabi; Fatemeh Ahadi; Farank Salman Nouri; Mohammad Hossein Ghahremani; Seyed Nasser Ostad; Atefeh Taheri Borougeni; Pooria Mansoori
Journal:  Int J Mol Sci       Date:  2011-07-15       Impact factor: 5.923

Review 5.  Ribosome-inactivating proteins: from plant defense to tumor attack.

Authors:  Maddalena de Virgilio; Alessio Lombardi; Rocco Caliandro; Maria Serena Fabbrini
Journal:  Toxins (Basel)       Date:  2010-11-10       Impact factor: 4.546

6.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Authors:  Kelly K Curtis; John Sarantopoulos; Donald W Northfelt; Glen J Weiss; Kerry M Barnhart; John K Whisnant; Carola Leuschner; Hector Alila; Mitesh J Borad; Ramesh K Ramanathan
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-08       Impact factor: 3.333

Review 7.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells.

Authors:  Jaleh Varshosaz; Ali Jahanian-Najafabadi; Jila Ghazzavi
Journal:  IET Nanobiotechnol       Date:  2016-08       Impact factor: 1.847

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.